



Press Release |

IBA – EXCLUSIVE SUPPLIER OF RADIOPHARMACEUTICALS IN ANDALUSIA

Embargo until 5:40 pm – December 13, 2006

Louvain-la-Neuve, Belgium, December 13, 2006 – IBA (Ion Beam Applications S.A.: Reuters IOBAAt.BR and Bloomberg IBAB.BB) announced today that it has been selected by the *Servicio Andaluz de Salud* (the regional Health Authorities of Andalusia) as the exclusive supplier of FDG (Fluorodeoxyglucose) and other Radiopharmaceuticals to all public hospitals of Andalusia.

The exclusivity has been granted following a public tender to supply Radiopharmaceuticals during a period of four years starting end 2006. IBA has started to supply FDG from its two production sites in Andalusia and other SPECT (Single Photon Emission Computed Tomography) radiopharmaceuticals from 12 radiopharmacies located within hospitals-customers sites. IBA has recently hired 24 people to work from these twelve radiopharmacies.

This tender will provide revenue to IBA of over EUR 31 million spread over four years, but with negligible EBIT in 2007 due to a level of startup investments that will be the base for future development of activities in Spain.

Andalusia, with almost a fifth of the Spanish population is a leading region for Nuclear Medicine, with the largest number of indications authorized for reimbursement in PET scanning.

“Winning this tender underlines the recognition of IBA as an expert in production and distribution of FDG and other radiopharmaceuticals. It also reinforces the position of IBA as the largest radiopharmaceuticals distribution network in Europe. IBA remains committed to developing the most advanced and complete PET radiopharmaceuticals distribution network throughout the world,” said Pierre Mottet, IBA’s Chief Executive Officer.



Press Release |

ABOUT IBA

IBA delivers solutions of a unique precision in the fields of **cancer diagnosis and therapy**. The company also offers sterilization and ionization solutions to improve the hygiene and safety of everyday life. IBA is listed on the pan-European stock exchange EURONEXT, is integrated into the NextEconomy market segment and belongs to the BelMid index.

Website: <http://www.iba-worldwide.com>.

Contact

IBA

Paul-Emmanuel Goethals
Director, Corporate Business Development
& Investor Relations
Phone: +32 10 47 58 16
paul-emmanuel.goethals@iba-group.com